Deutsche Bank’s Aegerion Pharmaceuticals AEGR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q4 | – | Sell |
-7,105
| Closed | -$21K | – | 5252 |
|
|
2016
Q3 | $21K | Sell |
7,105
-40,199
| -85% | -$69.7K | ﹤0.01% | 4530 |
|
|
2016
Q2 | $70K | Sell |
47,304
-86,514
| -65% | -$198K | ﹤0.01% | 4270 |
|
|
2016
Q1 | $494K | Buy |
133,818
+115,653
| +637% | +$716K | ﹤0.01% | 3224 |
|
|
2015
Q4 | $182K | Sell |
18,165
-103,998
| -85% | -$1.25M | ﹤0.01% | 3770 |
|
|
2015
Q3 | $1.66M | Buy |
122,163
+44,823
| +58% | +$798K | ﹤0.01% | 2607 |
|
|
2015
Q2 | $1.47M | Buy |
77,340
+61,384
| +385% | +$1.33M | ﹤0.01% | 2706 |
|
|
2015
Q1 | $415K | Sell |
15,956
-16,832
| -51% | -$428K | ﹤0.01% | 3402 |
|
|
2014
Q4 | $685K | Sell |
32,788
-7,408
| -18% | -$187K | ﹤0.01% | 3464 |
|
|
2014
Q3 | $1.34M | Sell |
40,196
-59,945
| -60% | -$1.86M | ﹤0.01% | 2811 |
|
|
2014
Q2 | $3.21M | Sell |
100,141
-396,049
| -80% | -$14.7M | ﹤0.01% | 2142 |
|
|
2014
Q1 | $22.9M | Sell |
496,190
-9,265
| -2% | -$543K | 0.02% | 851 |
|
|
2013
Q4 | $35.9M | Sell |
505,455
-90,629
| -15% | -$6.93M | 0.03% | 628 |
|
|
2013
Q3 | $51.1M | Buy |
596,084
+313,454
| +111% | +$26.6M | 0.04% | 491 |
|
|
2013
Q2 | $17.9M | Buy |
+282,630
| New | +$15M | 0.01% | 924 |
|
Deutsche Bank's AEGR Position: Q4 2016 in Review
Deutsche Bank sold out of Aegerion Pharmaceuticals (AEGR) in Q4 2016, closing a stake of 7,105 shares — an estimated $21K sold.
Deutsche Bank first reported a position in AEGR in Q2 2013 and held it in 14 quarters. The position peaked at $51.1M in Q3 2013. 0 funds tracked by Wall St. Rank hold AEGR as of Q4 2016.
- Deutsche Bank reported no remaining Aegerion Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
- Deutsche Bank sold 7,105 Aegerion Pharmaceuticals shares in Q4 2016, an estimated $21K.
- Deutsche Bank first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 14 quarters.
- Deutsche Bank's Aegerion Pharmaceuticals position peaked at $51.1M in Q3 2013.
- 0 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q4 2016.
Based on Deutsche Bank's 13F filing for Q4 2016, filed 14 Feb 2017.